Tag Archives: Myocardial infarction

Judgment Day for Avandia

By Oriana Schwindt | Published: July 14, 2010
Judgment Day has finally arrived for GSK’s Avandia. FDA’s Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees met July 13 and 14 to finally recommend, after months of deck-stacking against GSK, that the drug be severely restricted, if not outright pulled from the market. In the vote, 12 of 33 panelists [...]
Posted in FDA, Regulatory | Also tagged , , , , , , | Leave a comment

Daiichi Sankyo Chief Talks Effient

By George Koroneos | Published: July 15, 2009
FDA, late Friday, approved Daiichi Sankyo and Eli Lilly’s Effient (prasugrel), a blood thinner designed to lower the chance of blood clots in patients undergoing angioplasty. The drug received a black box warning from the get go, warning doctors of an increased risk of bleeding. However, the fact that the two companies now have a [...]
Posted in News, Strategy, Technology | Also tagged , , , , , | 2 Comments